Compare BHC & ETV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHC | ETV |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1996 | 2005 |
| Metric | BHC | ETV |
|---|---|---|
| Price | $6.06 | $15.19 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 188.5K |
| Earning Date | 10-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 423.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,724,000,000.00 | N/A |
| Revenue This Year | $6.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.33 | $13.13 |
| 52 Week High | $8.00 | $15.49 |
| Indicator | BHC | ETV |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 53.60 |
| Support Level | $5.44 | $14.26 |
| Resistance Level | $6.31 | $15.40 |
| Average True Range (ATR) | 0.21 | 0.21 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 67.72 | 61.51 |
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.